argenex (NASDAQ:ARGX) Price Target Raised to $1,200.00

argenex (NASDAQ:ARGX) had its price target upped by Citizens Jmp from $932.00 to $1,200.00 in a research report report published on Tuesday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

A number of other analysts have also commented on ARGX. Robert W. Baird raised their price target on argenex from $867.00 to $932.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Bank of America upped their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Wedbush raised their target price on shares of argenex from $1,000.00 to $1,050.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company lifted their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research note on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, argenex currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,118.28.

argenex Price Performance

ARGX opened at $1,038.12 on Tuesday. The business has a 50 day simple moving average of $892.22 and a two-hundred day simple moving average of $825.72. The firm has a market capitalization of $64.94 billion, a price-to-earnings ratio of 39.87, a PEG ratio of 1.09 and a beta of 0.46. argenex has a one year low of $658.60 and a one year high of $1,039.30.

argenex (NASDAQ:ARGX) last posted its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. As a group, sell-side analysts expect that argenex will post 28.47 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

Hedge funds have recently bought and sold shares of the business. Whipplewood Advisors LLC purchased a new stake in argenex in the first quarter worth about $28,000. Eastern Bank bought a new position in shares of argenex during the second quarter valued at approximately $32,000. Sunbelt Securities Inc. purchased a new position in shares of argenex during the third quarter valued at approximately $36,000. Axiom Investment Management LLC purchased a new position in shares of argenex during the first quarter valued at approximately $50,000. Finally, WPG Advisers LLC boosted its position in shares of argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after purchasing an additional 13 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: HC Wainwright raised its price target to $1,202 and lifted long-term earnings forecasts. The firm increased its FY2027 EPS estimate to $34.82 from $34.38, FY2028 to $44.72 from $43.50, FY2029 to $56.38 from $53.47, and FY2030 to $76.63 from $64.39. HC Wainwright maintained its “Buy” rating, signaling confidence in argenx’s long-term growth. HC Wainwright Boosts argenx Price Target
• Positive Sentiment: Other analysts also increased their targets. Morgan Stanley raised its target to $1,230, Wedbush lifted its target to $1,150, and Citi reiterated a “Buy” rating. Citizens JMP and Piper Sandler also forecast substantial appreciation potential, reinforcing the positive analyst sentiment. Wedbush Raises argenx Price Target Morgan Stanley Raises argenx Price Target argenx Receives a Buy from Citi
• Positive Sentiment: Oppenheimer said recent myositis data helps derisk the opportunity for Vyvgart. The assessment supports investor expectations that argenx may expand Vyvgart’s commercial reach and sustain revenue growth. argenx Myositis Data Derisk Vyvgart Opportunity
• Neutral Sentiment: The stock’s valuation is elevated, with a price-to-earnings ratio near 40, so continued gains depend on argenx converting its clinical pipeline and Vyvgart opportunity into the strong earnings growth analysts now project.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.